Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study aims to tailor PKU drug dosing for patients with organ impairment

NCT ID NCT07713758

Not yet recruiting Knowledge-focused Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study looks at how the body processes repinatrabit (JNT-517), an oral tablet for phenylketonuria, in people with moderate liver impairment or severe kidney impairment. It compares these results to those from healthy volunteers of similar age, weight, and sex. The goal is to understand if organ impairment changes drug levels in the blood, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
repinatrabit (JNT-517) oral tablet
What this could lead to
If successful, this study could help determine the right dose of repinatrabit for people with phenylketonuria who also have liver or kidney problems.
What could go wrong
This is a small, early-phase study focused on drug processing, not on treating the disease. Results may not predict how well the drug works or its safety in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

phenylketonuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHENYLKETONURIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.